Prospective pregnancy reports with a known pregnancy outcome, for women exposed to HPV-16/18 vaccine within the pre-defined risk period^* (N = 226)

Trimester of exposure	Outcome classified with no congenital abnormality				Outcome classified with a congenital abnormality				Total
	Live birth	Stillbirth	Elective termination	Spontaneous abortion	Live birth	Stillbirth	Elective termination	Spontaneous abortion
Within 60 days prior to pregnancy onset	51†	1	3	7	4	0	0	0	66
First trimester	103†	0	14	8	12	0	0	0	137
Second trimester	9‡	0	0	1	1	0	0	0	11
Third trimester	2‡	0	0	0	0	0	0	0	2
Unknown trimester	7	0	2	1	0	0	0	0	10
Total	172	1	19	17	17§¶	0	0	0	226

^*Risk period defined as vaccination with Cervarix® within 60 days prior to pregnancy onset up to whole duration of pregnancy. Multi-exposures during pregnancy:

^†Three cases were identified as having been exposed to Cervarix® more than once within 60 days and during the first trimester.

^‡One case was identified as having been exposed to Cervarix® more than once during the second and third trimesters.

^§For one case, the congenital anomaly was observed 1  year after birth.

^¶Five were classified as major structural defects including cardiac (2), palate (1), abdominal wall (1) and genital (1) structural defects, and 12 were classified as minor or non-structural anomalies.